← Back to Patent Explorer
US5030200A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for eradicating infectious biological contaminants in body tissues

Assignee: Baylor Research Institute
•
Filing: 1989-11-06
•
Granted: 1991-07-09
•
Expires: 2009-11-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method for externally eradicating infectious pathogenic contaminants, such as enveloped viruses, bacteria, trypanosomal and malarial parasites, present in body tissues, such as blood, blood components, semen, skin, and cornea, before the treated body tissues are introduced into, or transplanted onto, the body of a human or an animal. Such method includes the steps of: (1) admixing an effective, non-toxic amount of photoactive compound, which has a selectively for binding to the infectious pathogenic biological contaminants present therein, with the body tissues outside the body to produce resulting body tissues; (2) maintaining the resulting body tissues in a suitable container in which there is no net mass transfer, and (3) irradiating the resulting body tissues in the container for an effective period of time with an effective level of radiation such that the radiation penetrates the resulting body tissues and eradicates the photoactive-compound-bound contaminants present in the resulting body tissues and produces a decontaminated body tissue suitable for introducing into, or transplanting onto, the body of a human or animal.

Inventors

  • 👤 Millard M. Judy
  • 👤 James L. Matthews
  • 👤 Joseph T. Newman
  • 👤 Franklin Sogandares-Bernal

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 20:10
CPC Classifications
A; A61; A61L; A61L2/00; A61L2/02; A61L2/16; A61L2103/00; A61L2103/05; A61L2103/09

Claims Analysis

Total Claims: 70
Claim 1
Independent Claim 161 words
A method for eradicating infectious pathogenic biological contaminants from body fluid outside the body prior to introduction of the decontaminated body fluids into the body of a patient, said method comprising: admixing an effective, non-toxic amount of a photoactive compound with the body fluid to produce a resulting body fluid, the photoactive compound having an affinity to be selectively bound to the contaminants; maintaining the resulting body fluid in a suitable container in which there is no net mass transfer; and irradiating the resulting body fluid in the container with an effective level of essentially uniform intensity of radiation in the region of the visible spectrum, with a wavelength range of from about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the resulting fluid and exposes the photoactive-compound-bound contaminants to the radiation so as to eradicate such contaminants while maintaining the viability of said body fluids to produce viable decontaminated body fluids.
Claim 2
Independent Claim 161 words
A method for eradicating infectious pathogenic biological contaminants from body fluid outside the body prior to introduction of the decontaminated body fluids into the body of a patient, said method comprising: admixing an effective, non-toxic amount of a photoactive compound with the body fluid to produce a resulting body fluid, the photoactive compound having an affinity to be selectively bound to the contaminants; maintaining the resulting body fluid in a suitable container in which there is no net mass transfer; and irradiating the resulting body fluid in the container with an effective level of essentially uniform intensity of radiation in the region of the visible spectrum, with a wavelength range of from about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the resulting fluid and exposes the photoactive-compound-bound contaminants to the radiation so as to eradicate such contaminants while maintaining the viability of said body fluids to produce viable decontaminated body fluids.
Claim 3
Dependent Claim 30 words
The method as recited in claim 1 further comprising the step of selecting a body fluid from the group consisting of whole blood, blood plasma, serum, and fluids from plasmapheresis.
Claim 4
Dependent Claim 19 words
The method as recited in claim 1 further comprising the step of selecting a body fluid comprising of semen.
Claim 5
Dependent Claim 176 words
The method as recited in claim 1 further comprising the step of selecting a photoactive compound comprising a mixture of porphyrins, at least a portion of the molecules of said porphyrin mixture having the molecular formula: ##STR2## said molecules with said formula being fluorescent, photosensitizing, having the capability of selectively binding to said pathogenic biological contaminants, forming a high molecular weight aggregate with absorption peaks in the visible spectrum in water at approximately 365, 505, 537, 575, and 615 nanometers, absorption peaks in the infrared spectrum at approximately 3.0, 3.4, 6.4, 7.1, 8.1, 9.4, 12 and 15 microns, absorption peaks in carbon-13 nuclear magnetic resonance study at at least approximately 9.0, 18.9, 24.7, 34.5, 62, 94.5, 130-145, 171.7 ppm relative to a 37.5 ppm resonance peak of dimethyl sulfoxide and additional absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 27.9 ppm and 68.4 ppm relative to the resonance peak of tetramethylsilane in deuterated chloroform solvent; and at least 50 percent of the porphyrins in said mixture being of said molecules having said molecular formula.
Claim 6
Dependent Claim 32 words
The method as recited in claim 4 wherein the amount of said mixture of porphyrins admixed with said fluid is from about 0.1 to about 50 micrograms per milliliter of body fluid.
Claim 7
Dependent Claim 31 words
The method as recited in claim 5 wherein the amount of said mixture of porphyrins admixed with said fluid is from about 2 to 50 micrograms per milliliter of body fluid.
Claim 8
Dependent Claim 43 words
The method as recited in claim 1 wherein the level of radiation is produced by a light source having a wavelength of from about 400 to about 1000 nm and an energy density of from about 0.1 to about 50 J/cm 2 .
Claim 9
Dependent Claim 42 words
The method as recited in claim 7 wherein the level of radiation is produced by a light source having a wavelength of from about 600 to about 700 nm and an energy density from about 1 to about 20 J/cm 2 .
Claim 10
Dependent Claim 24 words
The method as recited in claim 1 further comprising the step of selecting body fluid which contains pathogenic biological contaminants comprising an envelope-containing virus.
Claim 11
Dependent Claim 28 words
The method as recited in claim 9 further comprising the step of selecting the envelope-containing virus from the group consisting of Herpesviridae, Poxviridae, Iridoviridae, Hepadnaviridae, Orthomyxoviridae, and Paramyxoviridae.
Claim 12
Dependent Claim 27 words
The method as recited in claim 9 further comprising the step of selecting the envelope-containing virus from the group consisting of Rhabdoviridae, Bunyaviridae, Filoviridae, Nodaviridae, and Togaviridae.
Claim 13
Dependent Claim 25 words
The method as recited in claim 9 further comprising the step of selecting the envelope-containing virus from the group consisting of Flaviviridae, Retroviridae, and Arenaviridae.
Claim 14
Dependent Claim 20 words
The method as recited in claim 12 further comprising the step of selecting the Retroviridae comprising a human immunodeficiency virus.
Claim 15
Dependent Claim 34 words
The method as recited in claim 1 further comprising the step of selecting body fluid which contains pathogenic biological contaminants comprising a bacteria selected from the group consisting of Streptococcus faecalis and Bacillus subtilis.
Claim 16
Dependent Claim 25 words
The method as recited in claim 1 further comprising the step of selecting body fluid which contains pathogenic biological contaminants comprising a Borrelia burgdorferi bacteria.
Claim 17
Dependent Claim 24 words
The method as recited in claim 1 further comprising the step of selecting body fluid which contains pathogenic biological contaminants comprising a malarial parasite.
Claim 18
Dependent Claim 24 words
The method as recited in claim 1 further comprising the step of selecting body fluid which contains pathogenic biological contaminants comprising a trypanosomal parasite.
Claim 19
Dependent Claim 20 words
The method as recited in claim 1 further comprising the step of agitating the resulting body fluid in the container.
Claim 20
Dependent Claim 19 words
The method as recited in claim 18 wherein the step of agitating is carried out by moving the container.
Claim 21
Dependent Claim 22 words
The method as recited in claim 18 wherein the step of agitating is carried out by the aid of an agitating means.
Claim 22
Dependent Claim 15 words
The method as recited in claim 20 wherein said agitating means comprises an agitating object.
Claim 23
Dependent Claim 13 words
The method as recited in claim 1 wherein said container is kept static.
Claim 24
Independent Claim 324 words
A method for externally purifying a blood product to eradicate pathogenic biological contaminants selected from the group consisting of envelope-containing viruses, bacteria, malarial, and trypanosomal parasites prior to introduction of the decontaminated blood products intravenously into a patient, said method comprising: admixing an effective amount of a photoactive compound with the blood products to bind the contaminant with the photoactive compound, said photoactive compound comprising a mixture of porphyrins, at least a portion of the molecules of said porphyrin mixture having the molecular formula: ##STR3## said molecules with said formula being fluorescent, photosensitizing, having the capability of selectively binding to said pathogenic biological contaminants, forming a high molecular weight aggregate with absorption peaks in the visible spectrum in water at approximately 365, 505, 537, 575, and 615 nanometers, absorption peaks in the infrared spectrum at approximately 3.0, 3.4, 6.4, 7.1, 8.1, 9.4, 12 and 15 microns, absorption peaks in carbon-13 nuclear magnetic resonance study at at least approximately 9.0, 18.9, 24.7, 34.5, 62, 94.5, 130-145 , 171.7 ppm relative to a 37.5 ppm resonance peak of dimethyl sulfoxide and additional absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 27.9 ppm and 68.4 ppm relative to the resonance peak of tetramethylsilane in deuterated chloroform solvent; and at least 50 percent of the porphyrins in said mixture being of said molecules having said molecular formula; maintaining the blood product containing the porphyrins-bound contaminants in a suitable container, exposable to a radiation source capable of irradiating the blood product and in which there is no net mass transfer; and irradiating the blood product in the container with an essentially uniform intensity of radiation source in the region of visible spectrum, with a wavelength of from about 400 nm to about 1000 nm for an effective period of time to permit the radiation to penetrate through the blood product in the container and eradicate the contaminants while maintaining the viability of components in said blood product.
Claim 25
Independent Claim 324 words
A method for externally purifying a blood product to eradicate pathogenic biological contaminants selected from the group consisting of envelope-containing viruses, bacteria, malarial, and trypanosomal parasites prior to introduction of the decontaminated blood products intravenously into a patient, said method comprising: admixing an effective amount of a photoactive compound with the blood products to bind the contaminant with the photoactive compound, said photoactive compound comprising a mixture of porphyrins, at least a portion of the molecules of said porphyrin mixture having the molecular formula: ##STR3## said molecules with said formula being fluorescent, photosensitizing, having the capability of selectively binding to said pathogenic biological contaminants, forming a high molecular weight aggregate with absorption peaks in the visible spectrum in water at approximately 365, 505, 537, 575, and 615 nanometers, absorption peaks in the infrared spectrum at approximately 3.0, 3.4, 6.4, 7.1, 8.1, 9.4, 12 and 15 microns, absorption peaks in carbon-13 nuclear magnetic resonance study at at least approximately 9.0, 18.9, 24.7, 34.5, 62, 94.5, 130-145 , 171.7 ppm relative to a 37.5 ppm resonance peak of dimethyl sulfoxide and additional absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 27.9 ppm and 68.4 ppm relative to the resonance peak of tetramethylsilane in deuterated chloroform solvent; and at least 50 percent of the porphyrins in said mixture being of said molecules having said molecular formula; maintaining the blood product containing the porphyrins-bound contaminants in a suitable container, exposable to a radiation source capable of irradiating the blood product and in which there is no net mass transfer; and irradiating the blood product in the container with an essentially uniform intensity of radiation source in the region of visible spectrum, with a wavelength of from about 400 nm to about 1000 nm for an effective period of time to permit the radiation to penetrate through the blood product in the container and eradicate the contaminants while maintaining the viability of components in said blood product.
Claim 26
Dependent Claim 33 words
The method as recited in claim 23 wherein the amount of said mixture of porphyrins admixed with said blood product is from about 0.1 to about 50 micrograms per milliliter of blood product.
Claim 27
Dependent Claim 33 words
The method as recited in claim 24 wherein the amount of said mixture of porphyrins admixed with said blood product is from about 2 to about 50 micrograms per milliliter of blood product.
Claim 28
Dependent Claim 43 words
The method as recited in claim 23 wherein the level of radiation is produced by a light source having a wavelength of from about 400 to about 700 nm and an energy density of from about 0.1 to about 50 J/cm 2 .
Claim 29
Dependent Claim 43 words
The method as recited in claim 26 wherein the level of radiation is produced by a light source having a wavelength of from about 600 to about 700 nm and an energy density of from about 1 to about 20 J/cm 2 .
Claim 30
Dependent Claim 24 words
The method as recited in claim 23 further comprising the step of selecting blood product which contains pathogenic biological contaminants comprising an envelope-containing virus.
Claim 31
Dependent Claim 28 words
The method as recited in claim 28 further comprising the step of selecting the envelope-containing virus from the group consisting of Herpesviridae, Poxviridae, Iridoviridae, Hepadnaviridae, Orthomyxoviridae, and Paramyxoviridae.
Claim 32
Dependent Claim 27 words
The method as recited in claim 28 further comprising the step of selecting the envelope-containing virus from the group consisting of Rhabdoviridae, Bunyaviridae, Filoviridae, Nodaviridae, and Togaviridae.
Claim 33
Dependent Claim 25 words
The method as recited in claim 28 further comprising the step of selecting the envelope-containing virus from the group consisting of Flaviviridae, Retroviridae, and Arenaviridae.
Claim 34
Dependent Claim 20 words
The method as recited in claim 31 further comprising the step of selecting the Retroviridae comprising a human immunodeficiency virus.
Claim 35
Dependent Claim 34 words
The method as recited in claim 23 further comprising the step of selecting blood product which contains pathogenic biological contaminants comprising a bacteria selected from the group consisting of Streptococcus faecalis and Bacillus subtilis.
Claim 36
Dependent Claim 25 words
The method as recited in claim 23 further comprising the step of selecting body fluid which contains pathogenic biological contaminants comprising a Borrelia burgdorferi bacteria.
Claim 37
Dependent Claim 24 words
The method as recited in claim 23 further comprising the step of selecting blood product which contains pathogenic biological contaminants comprising a malarial parasite.
Claim 38
Dependent Claim 24 words
The method as recited in claim 23 further comprising the step of selecting blood product which contains pathogenic biological contaminants comprising a trypanosomal parasite.
Claim 39
Dependent Claim 20 words
The method as recited in claim 23 further comprising the step of agitating the resulting body fluid in the container.
Claim 40
Dependent Claim 19 words
The method as recited in claim 37 wherein the step of agitating is carried out by moving the container.
Claim 41
Dependent Claim 22 words
The method as recited in claim 37 wherein the step of agitating is carried out by the aid of an agitating means.
Claim 42
Dependent Claim 15 words
The method as recited in claim 39 wherein said agitating means comprises an agitating object.
Claim 43
Dependent Claim 13 words
The method as recited in claim 23 wherein said container is kept static.
Claim 44
Independent Claim 168 words
A method for extracorporeal treatment of the blood of a patient infected with infectious pathogenic biological contaminants said method comprising; removing blood from the body of a patient infected with infectious pathogenic biological contaminants; adding to said blood an effective, non-toxic amount of photoactive compound having an affinity to be selectively bound to the infectious contaminants; maintaining said treated blood in a suitable container in which there is not net mass transfer; irradiating said contaminated blood admixed with photo-active compound in the container with an effective level of essentially uniform intensity of radiation in the region of visible spectrum, with a wavelength range of from about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the blood and exposes the photoactive-compound-bound infectious contaminants to the radiation so as to eradicate such infectious contaminants while maintaining the viability of components in said blood to produce a viable and decontaminated blood; and returning said viable and decontaminated blood to the patient's body.
Claim 45
Independent Claim 168 words
A method for extracorporeal treatment of the blood of a patient infected with infectious pathogenic biological contaminants said method comprising; removing blood from the body of a patient infected with infectious pathogenic biological contaminants; adding to said blood an effective, non-toxic amount of photoactive compound having an affinity to be selectively bound to the infectious contaminants; maintaining said treated blood in a suitable container in which there is not net mass transfer; irradiating said contaminated blood admixed with photo-active compound in the container with an effective level of essentially uniform intensity of radiation in the region of visible spectrum, with a wavelength range of from about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the blood and exposes the photoactive-compound-bound infectious contaminants to the radiation so as to eradicate such infectious contaminants while maintaining the viability of components in said blood to produce a viable and decontaminated blood; and returning said viable and decontaminated blood to the patient's body.
Claim 46
Dependent Claim 176 words
The method as recited in claim 42 further comprising the step of selecting a photoactive compound comprising a mixture of porphyrins, at least a portion of the molecules of said porphyrin mixture having the molecular formula: ##STR4## said molecules with said formula being fluorescent, photosensitizing, having the capability of selectively binding to said pathogenic biological contaminants, forming a high molecular weight aggregate with absorption peaks in the visible spectrum in water at approximately 365, 505, 537, 575, and 615 nanometers, absorption peaks in the infrared spectrum at approximately 3.0, 3.4, 6.4, 7.1, 8.1, 9.4, 12 and 15 microns, absorption peaks in carbon-13 nuclear magnetic resonance study at at least approximately 9.0, 18.9, 24.7, 34.5, 62, 94.5, 130-145, 171.7 ppm relative to a 37.5 ppm resonance peak of dimethyl sulfoxide and additional absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 27.9 ppm and 68.4 ppm relative to the resonance peak of tetramethylsilane in deuterated chloroform solvent; and at least 50 percent of the porphyrins in said mixture being of said molecules having said molecular formula.
Claim 47
Dependent Claim 33 words
The method as recited in claim 43 further comprising the step of administering said mixture of porphyrins to the patient prior to the removal of the blood from the patient's body for irradiation.
Claim 48
Dependent Claim 37 words
The method as recited in claim 44 further comprising the step of administering said mixture of porphyrins to the patient between about thirty minutes and about one week prior to removal of the patient's blood for irradiation.
Claim 49
Dependent Claim 36 words
The method as recited in claim 44 further comprising the step of administering said mixture of porphyrins at a dosage from about 0.5 mg to about 40 mg per kg of body weight of the patient.
Claim 50
Dependent Claim 35 words
The method as recited in claim 42 further comprising the step of admixing said mixture of porphyrins with said blood in an amount from about 0.1 to about 50 micrograms per milliliter of said blood.
Claim 51
Dependent Claim 35 words
The method as recited in claim 47 further comprising the step of admixing said mixture of porphyrins with said blood in an amount from about 2 to about 50 micrograms per milliliter of said blood.
Claim 52
Dependent Claim 43 words
The method as recited in claim 42 wherein the level of radiation is produced by a light source having a wavelength of from about 600 to about 1000 nm and an energy density of from about 1 to about 50 J/cm 2 .
Claim 53
Dependent Claim 43 words
The method as recited in claim 49 wherein the level of radiation is produced by a light source having a wavelength of from about 600 to about 700 nm and an energy density of from about 1 to about 20 J/cm 2 .
Claim 54
Dependent Claim 24 words
The method as recited in claim 42 further comprising the step of selecting a blood which contains pathogenic biological contaminants comprising an envelope-containing virus.
Claim 55
Dependent Claim 28 words
The method as recited in claim 51 further comprising the step of selecting the envelope-containing virus from the group consisting of Herpesviridae, Poxviridae, Iridoviridae, Hepadnaviridae, Orthomyxoviridae, and Paramyxoviridae.
Claim 56
Dependent Claim 27 words
The method as recited in claim 51 further comprising the step of selecting the envelope-containing virus from the group consisting of Rhabdoviridae, Bunyaviridae, Filoviridae, Nodaviridae, and Togaviridae.
Claim 57
Dependent Claim 25 words
The method as recited in claim 51 further comprising the step of selecting the envelope-containing virus from the group consisting of Flaviviridae, Retroviridae, and Arenaviridae.
Claim 58
Dependent Claim 20 words
The method as recited in claim 54 further comprising the step of selecting the Retroviridae comprising a human immunodeficiency virus.
Claim 59
Dependent Claim 34 words
The method as recited in claim 42 further comprising the step of selecting a blood which contains pathogenic biological contaminants comprising a bacteria selected from the group consisting of Streptococcus faecalis and Bacillus subtilis.
Claim 60
Dependent Claim 25 words
The method as recited in claim 42 further comprising the step of selecting body fluid which contains pathogenic biological contaminants comprising a Borrelia burgdorferi bacteria.
Claim 61
Dependent Claim 21 words
The method as recited in claim 42 further comprising the step of selecting the pathogenic biological contaminants comprising a malarial parasite.
Claim 62
Dependent Claim 24 words
The method as recited in claim 42 further comprising the step of selecting a blood which contains pathogenic biological contaminants comprising a trypanosomal parasite.
Claim 63
Dependent Claim 20 words
The method as recited in claim 42 further comprising the step of agitating the resulting body fluid in the container.
Claim 64
Dependent Claim 19 words
The method as recited in claim 60 wherein the step of agitating is carried out by moving the container.
Claim 65
Dependent Claim 22 words
The method as recited in claim 60 wherein the step of agitating is carried out by the aid of an agitating means.
Claim 66
Dependent Claim 15 words
The method as recited in claim 62 wherein said agitating means comprises an agitating object.
Claim 67
Dependent Claim 13 words
The method as recited in claim 42 wherein said container is kept static.
Claim 68
Independent Claim 184 words
A method for extracorporeal treatment of the blood of a patient infected with infectious pathogenic biological contaminants said method comprising: administering to the patient infected with infectious pathogenic foreign biological contaminants an effective, non-toxic amount of photoactive compound having an affinity to be selectively bound to the infectious contaminants; waiting a period of time for the photoactive compound to be taken up by the blood; removing the blood from the body of the patient; maintaining the blood in a suitable container in which there is no net mass transfer; irradiating the blood admixed with photoactive compound in the container with an effective level of essentially uniform intensity of radiation in the region of visible spectrum, with a wavelength range of from about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the blood and exposes the photoactive-compound-bound infectious contaminants to the radiation so as to eradicate such infectious contaminants while maintaining the viability of components in said blood to produce a viable and decontaminated blood; and returning the viable and decontaminated blood to the patient's body.
Claim 69
Independent Claim 184 words
A method for extracorporeal treatment of the blood of a patient infected with infectious pathogenic biological contaminants said method comprising: administering to the patient infected with infectious pathogenic foreign biological contaminants an effective, non-toxic amount of photoactive compound having an affinity to be selectively bound to the infectious contaminants; waiting a period of time for the photoactive compound to be taken up by the blood; removing the blood from the body of the patient; maintaining the blood in a suitable container in which there is no net mass transfer; irradiating the blood admixed with photoactive compound in the container with an effective level of essentially uniform intensity of radiation in the region of visible spectrum, with a wavelength range of from about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the blood and exposes the photoactive-compound-bound infectious contaminants to the radiation so as to eradicate such infectious contaminants while maintaining the viability of components in said blood to produce a viable and decontaminated blood; and returning the viable and decontaminated blood to the patient's body.
Claim 70
Dependent Claim 22 words
The method as recited in claim 65 wherein the waiting period of time is from about one hour to about one week.

References Cited (Backward Citations)

US4614190A Cited
US4649151A Cited
US4613322A Cited
US4684521A Cited
US4708715A Cited
US4878891A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-07-08 1995-01-07 1995-07-09 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-07-08 1999-01-07 1999-07-09 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-07-08 2003-01-07 2003-07-09 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag